Amiodarone-induced bronchiolitis obliterans organizing pneumonia (BOOP)  by Oren, S. et al.
Respiratory Medicine (1996) 90, 167-l 69 
Case Reports 
Amiodarone-induced bronchiolitis obliterans organizing 
pneumonia (BOOP) 
S. OREN*II, S. TURKOT*, B. GOLZMAN*, D. LONDON?, D. BEN-D• R$ AND Z. WEILER~ 
*Department of Internal Medicine, t Ultrasound Unit, IDepartment of Pathology and §Respiratory Unit, 
Barzilai Medical Center, Ashkelon, Israel 
Introduction 
Amiodarone hydrochloride is a very effective anti- 
arrhythmic but its use is often associated with serious 
pulmonary complications (1). The mechanisms re- 
sponsible for the drug toxicity are unknown. Both 
hypersensitivity reaction to amiodarone (2,3) and 
dose-dependent direct cytotoxicity (4-6) have been 
suggested. Amiodarone-associated pulmonary tox- 
icity (APT) has been reported to occur in l-17% of 
treated cases and to have a potentially fatal course 
(7-10). We report two cases of patients treated with 
amiodarone who developed bronchiolitis obliterans 
organizing pneumonia (BOOP), one of whom was 
diagnosed only at post-mortem examination. 
Case Reports 
CASE NO. 1 
A 61-year-old man was admitted to the Internal 
Medicine Department complaining of dyspnoea, 
cough and fever lasting for 3 months. The patient 
had hypertension, congestive heart failure due to 
severe mitral regurgitation, and recurrent episodes of 
paroxysmal atria1 fibrillation. He had been treated 
with furosemide, enalapril, digoxin, warfarin and 
amiodarone HCL for 3 yr. The amiodarone dosage 
varied between 400 and 800 mg day - ‘. On admis- 
sion, the patient had shortness of breath, a tempera- 
ture of 385”C, blood pressure of 160/92 mmHg, and 
a regular heart rate of 96 bpm. His neck veins were 
distended, rales were heard over both lung fields, and 
IV/VI systolic murmur was heard over the chest 
radiating to the axilla. The liver was slightly enlarged 
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and ankle oedema was absent. Chest X-ray disclosed 
diffuse interstitial pulmonary infiltrate occasionally 
alveolar in distribution, which was attributed to 
probable congestive heart failure. However, aggres- 
sive diuretic treatment was not accompanied by 
change in the radiographic findings. 
Laboratory findings: ESR 90mm h-i, Hb 
11.8gdl-‘, WBC 12 600ml-‘. Blood, urine and 
sputum cultures were negative. Serologic tests for 
possible infectious agents were negative. Acid-fast 
bacilli were not found in sputum or gastric content. 
Protein electrophoresis, complement pathway, 
antibodies to parietal cells, smooth muscle, anti- 
neutrophilic cytoplasmatic antibodies (ANCA), and 
tumour markers were within normal values. 
Transthoracic and transoesophageal echocardi- 
ography failed to find cardiac vegetations. Com- 
puterized tomography (CT) of the abdomen was 
normal, and diffuse alveolar infiltrates were seen on 
chest CT. Bronchoscopy with lung biopsy disclosed 
organizing pneumonia with fibrin in small bronchi- 
oles, foam cells, and interstitial fibrosis - findings 
consistent with BOOP. 
As aetiologies such as congestive heart failure, 
vasculitis, infection or malignancy were excluded, the 
clinical and radiographic findings in this patient 
treated with 400-800 mg day - ’ of amiodarone over 
a long period were attributed to the APT. The 
amiodarone was withheld, and glucocorticoids were 
given orally at an initial dose of 60 mg dl - ‘, tapered 
off slowly and discontinued after 2 months. The fever 
and cough disappeared immediately, and the short- 
ness of breath and radiographic findings improved 
significantly within I month. 
CASE NO. 2 
A 66-year-old man was hospitalized due to fever, 
cough, and shortness of breath for 3 weeks. Four 
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months earlier, he had had an episode of transient 
ischaemic attack. Brain CT at that time disclosed 
right temporo-parietal infarction, and a trans- 
oesophageal echocardiography revealed a thrombus 
in the left atria1 auricle. The patient was treated with 
warfarin. Two months later, he had an acute anterior 
wall myocardial infarction complicated with peri- 
carditis and recurrent episodes of paroxysmal atria1 
fibrillation. He was discharged with warfarin, 
nitrates, enalapril and amiodarone (800 mg day ~ I), 
with instructions to gradually reduce its dosage to 
200mgday-I. 
At the present admission, the patient had a tem- 
perature of 39”C, arterial pressure of 140170 mmHg, 
and a regular heart rate of 95 bpm. Inspiratory rales 
were heard over the bases of the lungs. Oii chest 
X-ray, diffuse interstitial infiltrations were observed. 
Laboratory findings: ESR 50 mm h- ‘, WBC 12 
600 ml - ‘, Hb 12.4 g dl ~ ‘, slightly elevated liver en- 
zymes and marked elevation of lactic dehydrogenase. 
Arterial blood gases were PO, 59 mmHg and PaCO, 
32 mmHg. His fever seemed septic, with spikes of 
3940” and shivering. Although blood, urine and 
sputum cultures were negative and various serologic 
tests including cold agglutinin, Weil-Felix, HIV, IgM 
to CMV and EBV, HB,Ag, Brucella, Vidal, comp- 
lement fixation to Rickettsia, and Legionella were 
all non-diagnostic, infectious aetiology was still sus- 
pected and the patient was treated with erythromycin, 
cetriaxone, vancomycin i.v. and a nasal oxygen sup- 
ply. Warfarin and amiodarone treatment was discon- 
tinued due to the remote possibility of lung bleeding 
or toxicity. Ventilation-perfusion lung scan did not 
support a diagnosis of pulmonary embolism. Trans- 
oesophageal echocardiography did not demonstrate 
cardiac vegetations. 
Abdominal ultrasound and CT were normal. On 
chest CT, bilateral interstitial involvement with thick- 
ening of the interlobular septa and with patches of 
hazy increased density surrounding nearby vessels 
was seen (Plate 1). On gallium scan, increased lung 
uptake was found. Bronchoscopy with lavage showed 
patent airways with proteinous amorphous material 
with no organisms. 
The patient’s medical condition deteriorated, 
accompanied by severe hypoxia, a rise in liver 
enzymes and a decline in kidney function. He 
was intubated and mechanically ventilated with 
increasing oxygen concentrations and higher positive 
pressure. Imipenem and glucocorticoids were added, 
with no significant response. Open lung biopsy was 
performed, but the patient died the same day. 
The open lung biopsy and the post-mortem exam- 
ination were not consistent with bronchopneumonia; no 
Plate I Chest CT scan showing bilateral pulmonary infil- 
trate in Patient No. 2. 
granulomas or inclusion bodies were found, and specific 
stains for acid-fast bacilli. Pneumocystis carini and fungi 
were negative. Extensive intra-alveolar organizing pneu- 
monia with focal hyaline membrane was seen, and inter- 
stitial infiltration with mononuclear cells, metaplastic 
changes of the alveolar type II cells, alveolar septal 
thickening, and fibrosis were documented. 
Discussion 
There are no laboratory or clinical data currently 
available that, alone, unequivocally establish the 
diagnosis of APT. To make a clinical diagnosis of 
APT requires the exclusion of other diagnostic pos- 
sibilities together with a reasonable constellation of 
symptoms or findings consistent with the following: 
(a) new or worsening symptoms; (b) new or worsen- 
ing abnormalities seen upon chest X-ray; or (c) a 
decline of at least 15% in the CO diffusion capacity 
(DLCO) or total lung capacity (7-10). Several ad- 
ditional factors should be considered in the establish- 
ment of a ‘clinical’ diagnosis of APT: (a) the absence 
of phospholipidosis in lung cells makes the diagnosis 
unlikely; (b) a marked CD8+ lymphocytosis in the 
lavage is strongly supportive; (c) lung biopsy material 
that reveals diffuse alveolar damage, interstitial pneu- 
monitis, or fibrosis is consistent with APT; and (d) 
drug withdrawal with or without steroid therapy 
should in most cases reverse some or all of the 
abnormalities in APT (11). 
The two patients under discussion had APT with 
typical presenting symptoms of this entity: dyspnoea, 
cough and fever (3). Their chest X-ray and CT 
disclosed the characteristic findings of non-specific 
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pulmonary infiltrate, both interstitial and alveolar 
(1,11,12). The DLCO was not assessed, and gallium 
scan showing increased uptake was only performed 
in the second patient. In the first patient, bron- 
choscopy with lung biopsy findings and clinical and 
radiographic improvement after drug withdrawal 
confirmed the diagnosis. In the second patient, 
broncho-alveolar lavage (13), open lung biopsy 
(7,10,14), and post-mortem examination helped us 
in making the correct diagnosis, although too late. 
Bronchiolitis obliterans organizing pneumonia is a 
disease entity proposed by Epler et al. (15) in 1985. 
Its histopathological features are patchy bronchiolitis 
obliterans with organizing pneumonia, accumulation 
of foamy cells in the peripheral air spaces, and 
interstitial infiltration of mononuclear cells (16). 
Clinically, it is characterized by flu-like illness with 
cough, fever, dyspnoea, and late respiratory crackles; 
roentgenographically by patchy infiltrates; and 
physiologically by decreased vital capacity and dif- 
fusing capacity (17). Various agents may be related to 
BOOP, and amiodarone is one of them (12,18). In the 
present study, as in the previous study of Camus et al. 
(18), the two patients with APT had reported 
histopathological evidence of BOOP. In both, the 
amiodarone was discontinued and glucocorticoids 
were initiated. However, due to a low index of 
suspicion and to rapid clinical deterioration, these 
steps were taken too late in the second patient, 
resulting in his death. 
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